Urinary levels of UBE2C could be used successfully to discriminate BC patients from non-cancer patients with hematuria (AUC, 0.839; sensitivity, 82.5%; and specificity, 76.2%) (Figure 3). This evidence concerns the gene UBE2C and breast cancer.